Exo Therapeutics
Juan Pablo Maianti is currently an Assistant Professor at the Albert Einstein College of Medicine since August 2022. As a co-founder and Employee 001 at Exo Therapeutics, a role held since September 2018, Juan Pablo has contributed significantly to the field. Prior experience includes serving as a Postdoctoral Researcher at the Broad Institute of MIT and Harvard from May 2015 to December 2018 and completing a PhD in Chemistry and Chemical Biology at Harvard University from August 2010 to May 2015, with a thesis focused on the therapeutic potential of Insulin-Degrading Enzyme. Earlier academic credentials include a Master's degree in Synthetic Organic Chemistry from Université de Montréal and a Bachelor's degree in Biochemistry from the University of Canterbury.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential toreprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.